搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Health on MSN
4 个月
What Are Eosinophils—and What Level Indicates Cancer?
Eosinophils are white blood cells that play an essential role in the immune system, specifically in fighting diseases and ...
Nature
3 年
Dexpramipexole targets eosinophilic inflammation
In the course of the ALS development program, however, dexpramipexole was observed to produce a significant and targeted depletion of eosinophils in the blood of ALS patients 4. Eosinophils are ...
11 天
直击ERS 2024热点研究,解锁EGPA靶向治疗前沿进展
9月7日至9月11日(奥地利维也纳时间),第34届欧洲呼吸学会(ERS 2024) 年会 盛大召开。来自全球各地的呼吸领域顶尖学者齐聚维也纳,为广大呼吸病学者带来了一场精彩的学术盛宴!
Medscape
11 天
Blood Eosinophil Counts Might be Predictor for Childhood Asthma and Treatment Response
A deep-dive analysis of preschoolers' lungs can help pediatricians identify potential cases of asthma and responsiveness to ...
EuropaWire
3 天
FDA Approves AstraZeneca’s Fasenra for Eosinophilic Granulomatosis with Polyangiitis ...
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
WNEM Saginaw on MSN
1 天
Breakthrough for picky eaters: Hope for children with EoE
We’ve all seen them and some of us have one at home: picky eaters. A toddler that just won’t eat, no matter what you put on ...
Medscape
8 天
COPD: The ICS Triple Therapy Debate Heats Up
The modern debate over ICSs in COPD has the catnip required to produce an academic catfight. It pits "statements" against ...
Yahoo Finance
2 天
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
It is an interleukin (IL)-5 targeting monoclonal antibody that was first approved in 2015. Fasenra is a monoclonal antibody ...
FiercePharma
3 天
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune ...
“Our mechanism of action is indeed different to that of [Nucala]. They block the cytokine, we actually eliminate the ...
MedPage Today
12 天
Twice-Yearly Biologic Cuts Severe Asthma Exacerbation Rate in Half
The phase IIIA trials randomized 792 patients ages 12 and older with severe asthma in a 2:1 ratio to depemokimab (100 mg ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈